FeesSafety
Pluang+

Medline faces securities fraud probe after FDA cites manufacturing issues and stock drops.

Market News
18 Nov 2026, 13:36 WIB
GlobeNewsWire
View Source
Bearish
Medline faces securities fraud probe after FDA cites manufacturing issues and stock drops.

Medline Inc. is under investigation for potential securities fraud following FDA warnings about significant manufacturing violations. The FDA highlighted failures in investigating product quality discrepancies, leading to a 7% stock drop on June 2, 2026. Further admissions of earnings losses due to remediation efforts caused another 13% drop on August 5, 2026. Investors who suffered losses may have legal options and are encouraged to contact Bleichmar Fonti & Auld LLP for potential class action participation.

As of Nov 18, 2026 18:43 WIB, Medline Inc. Class A Common Stock (MDLN) trades on Pluang at USD 36.10, down 4.19% in the last day. The stock's market capitalization stands at $33.10 billion with a trading volume of 9,063,224 shares. This follows earlier significant price drops linked to the company's regulatory and earnings challenges, highlighting ongoing market sensitivity to MDLN's situation.

More News (MDLN)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App